Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies
Taylor Harding, Linda B. Baughn, Shaji Kumar, et al.
Leukemia (2019) Vol. 33, Iss. 4, pp. 863-883
Closed Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing
Yaël Cohen, Mor Zada, Shuang-Yin Wang, et al.
Nature Medicine (2021) Vol. 27, Iss. 3, pp. 491-503
Open Access | Times Cited: 184
Understanding Drug Sensitivity and Tackling Resistance in Cancer
Jeffrey W. Tyner, Franziska Haderk, Anbarasu Kumaraswamy, et al.
Cancer Research (2022) Vol. 82, Iss. 8, pp. 1448-1460
Open Access | Times Cited: 42
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells
Daniele Tibullo, Cesarina Giallongo, Alessandra Romano, et al.
Biomolecules (2020) Vol. 10, Iss. 5, pp. 696-696
Open Access | Times Cited: 50
hsa_circ_0007841: A Novel Potential Biomarker and Drug Resistance for Multiple Myeloma
Meng Gao, Chengyuan Li, Han Xiao, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 51
Long Noncoding RNA H19 Promotes Tumorigenesis of Multiple Myeloma by Activating BRD4 Signaling by Targeting MicroRNA 152-3p
Jifu Zheng, Ninghong Guo, Fuming Zi, et al.
Molecular and Cellular Biology (2019) Vol. 40, Iss. 3
Open Access | Times Cited: 45
The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma
Sylvia Faict, Inge Oudaert, Ludovic D’Auria, et al.
Cancers (2019) Vol. 11, Iss. 12, pp. 1823-1823
Open Access | Times Cited: 45
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression
Katia Beider, Valeria Voevoda-Dimenshtein, Ali Zoabi, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 26
Nontargeted and targeted metabolomics approaches reveal the key amino acid alterations involved in multiple myeloma
Lingling Yue, Pengyun Zeng, Yanhong Li, et al.
PeerJ (2022) Vol. 10, pp. e12918-e12918
Open Access | Times Cited: 25
An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
Jeffrey R. Sawyer, Erming Tian, Brian A. Walker, et al.
Blood Cancer Journal (2019) Vol. 9, Iss. 8
Open Access | Times Cited: 36
Latest perspectives on glucocorticoid-induced apoptosis and resistance in lymphoid malignancies
Dorien Clarisse, Fritz Offner, Karolien De Bosscher
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2020) Vol. 1874, Iss. 2, pp. 188430-188430
Open Access | Times Cited: 35
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling
Mario Russo, Luca Tirinato, Francesca Scionti, et al.
ACS Omega (2020) Vol. 5, Iss. 47, pp. 30436-30443
Open Access | Times Cited: 27
Downregulation of microRNA‑25‑3p inhibits the proliferation and promotes the apoptosis of multiple myeloma cells via targeting the PTEN/PI3K/AKT signaling pathway
Youmei Zi, Yingzi Zhang, Yanwei Wu, et al.
International Journal of Molecular Medicine (2020) Vol. 47, Iss. 3
Open Access | Times Cited: 25
Novel targets for the treatment of relapsing multiple myeloma
Nicola Giuliani, Fabrizio Accardi, Valentina Marchica, et al.
Expert Review of Hematology (2019) Vol. 12, Iss. 7, pp. 481-496
Closed Access | Times Cited: 25
Xanthohumol exhibits anti-myeloma activity in vitro through inhibition of cell proliferation, induction of apoptosis via the ERK and JNK-dependent mechanism, and suppression of sIL-6R and VEGF production
Adrianna Sławińska-Brych, Barbara Zdzisińska, Arkadiusz Czerwonka, et al.
Biochimica et Biophysica Acta (BBA) - General Subjects (2019) Vol. 1863, Iss. 11, pp. 129408-129408
Closed Access | Times Cited: 23
Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma
Irena Misiewicz-Krzemińska, Cristina de Ramón, Luís A. Corchete, et al.
Blood Advances (2020) Vol. 4, Iss. 23, pp. 6023-6033
Open Access | Times Cited: 23
Modulation of Cellular Redox Parameters for Improving Therapeutic Responses in Multiple Myeloma
Alessandro Allegra, Claudia Petrarca, Mario Di Gioacchino, et al.
Antioxidants (2022) Vol. 11, Iss. 3, pp. 455-455
Open Access | Times Cited: 14
Inhibition of CARM1 suppresses proliferation of multiple myeloma cells through activation of p53 signaling pathway
Lan Yang, Le Ma, Qiang Gong, et al.
Molecular Biology Reports (2023) Vol. 50, Iss. 9, pp. 7457-7469
Open Access | Times Cited: 7
Hypoxic Bone Marrow Stromal Cells Secrete miR-140–5p and miR-28–3p That Target SPRED1 to Confer Drug Resistance in Multiple Myeloma
Hui Zhang, Zhimin Du, Chenggong Tu, et al.
Cancer Research (2023) Vol. 84, Iss. 1, pp. 39-55
Closed Access | Times Cited: 7
Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma
Yu-Hsiu T. Lin, Gregory P. Way, Benjamin G. Barwick, et al.
Blood Advances (2019) Vol. 3, Iss. 21, pp. 3214-3227
Open Access | Times Cited: 22
A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche
Antonio Giovanni Solimando, Angelo Vacca, Doménico Ribatti
Journal of Oncology (2020) Vol. 2020, pp. 1-16
Open Access | Times Cited: 18
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
Parvathi Sudha, Aarif Ahsan, Cody Ashby, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 13, pp. 2854-2864
Open Access | Times Cited: 11
A functional three-dimensional microphysiological human model of myeloma bone disease
Richard Visconti, Kyle L. Kolaja, Jessica Cottrell
Journal of Bone and Mineral Research (2020) Vol. 36, Iss. 10, pp. 1914-1930
Open Access | Times Cited: 15
Long non‑coding RNA DANCR represses the viability, migration and invasion of multiple myeloma cells by sponging miR‑135b‑5p to target KLF9
Linlin Wu, Liang Xia, Huimin Jiang, et al.
Molecular Medicine Reports (2021) Vol. 24, Iss. 3
Open Access | Times Cited: 13
Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-κB Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells
Masanobu Tsubaki, Tomoya Takeda, Takuya Matsuda, et al.
Biomedicines (2021) Vol. 9, Iss. 1, pp. 33-33
Open Access | Times Cited: 11
Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma
Angélique Bruyer, Laure Dutrieux, Hugues de Boussac, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top